EN DE
Watch Athens Medical C.S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Athens Medical C.S.A. (IATR) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Athens Medical C.S.A. stock €2.28, price €1.39, upside +64.0%, quality 33 out of 100. Rating: strongly undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GR · ISIN GRS147233001

AM Athens Medical C.S.A. logo Some data Nov 8, 2026

Athens Medical C.S.A.

IATR · AT
Cheap, value-trap risk

The stock costs 39% less than our calculation considers fair.

Fair value €2.28 · Strongly undervalued
Expensive Growth (revenue 5y +8.0 %/yr in EUR)
Moderate debt
Some data
Quality 33/100
Loss-making · -1.7% net margin (TTM)
Negative free cash flow
Trails peers (5/13)
Narrow moat 13/100 · thin data
Watch Athens Medical C.S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€2.30 €1.25 Fair Value €2.28 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range €1.25 – €2.30 · fair‑value band €1.34 – €3.22 · the €1.39 price screens below the €2.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Athens Medical C.S.A. in your weekly email

Every Wednesday you see whether Athens Medical C.S.A. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally.

Show moreShow less

The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, gynecologic, and urology services; and neuro- and spine surgery services.

It also provides medical services for range of orthopedics, such as foot and ankle, hand and wrist, hip, knee, shoulder, and spine; sports injuries; plastic Surgeries for face, body, breast, obesity, reconstructive plastic surgery, scar correction, and sex reassignment; bariatric surgery for gastric banding, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch; and chronic diseases, including diabetes, endocrinology, heat failure, high blood pressure, pain management, respiratory system, stroke, and thyroid conditions.

In addition, the company operates wellness and prevention centers; and offers medical education, training, and practice services. The company was founded in 1983 and is based in Athens, Greece.

Stock analysis

Athens Medical C.S.A. (IATR) currently trades at €1.39, while our model-based Fair Value estimate is €2.28, implying the stock looks roughly 39% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the data coverage at medium.

Scenario range: €1.34 (bear) to €3.22 (bull), the price of €1.39 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Athens Medical C.S.A. reported revenue of €276M in FY2025 versus €226M in FY2021, a compound +5.1%/yr. Reported net income was −€4.7M in FY2025.

Key figures

Market cap €121M Micro · P/S ratio 0.48 · EPS (TTM) €−0.0500 · Dividend yield 1.3% · Net margin −1.7% · Return on equity −4.3% · Return on assets (EBIT) 3.4% (5-year average) · Operating margin −0.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 64%, IATR screens cheaper than that median.

Fair Value models

Bear €1.34 Fair Value €2.28 Bull €3.22
Price €1.39 · Upside +64.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA €1.34 €2.28 €3.22 65
NCAV (Graham) €0.5600 €0.7500 €1.11 54
All 2 models by family
Multiples
EV/EBITDA €1.34 €2.28 €3.22 65
Asset-Based
NCAV (Graham) €0.5600 €0.7500 €1.11 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 12
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.2% (2020) → 1.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch IATR, get fair value alerts →

Compare Athens Medical C.S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside +66.4% · Top 25%
Profitability
Return on assets −0.9% · Bottom 25%
Net margin (12 months) −1.7% · Bottom 25%
Operating margin (12 months) −0.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.8% · Below median
Dividend yield (12 months) 1.3% · Below median
Balance sheet
Debt / equity 0.58× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.14× · Cheaper than median
P/S (12 months) 0.43× · Cheapest 25%
EV/EBITDA 7.5× · Cheaper than median
PEG 0.93× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)19 · sector 31
PAST (return on equity)0 · sector 33
HEALTH (low debt)71 · sector 90
DIVIDEND (yield)26 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs IATR
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs IATR
DaVita Inc DVA $191.35 $218.90 +14% vs IATR
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs IATR
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs IATR
The Ensign Group ENSG $181.08 $140.09 −23% vs IATR
Encompass Health Corporation EHC $137.54 $94.81 −31% vs IATR
Fresenius SE FRE €52.48 €34.77 −34% vs IATR
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs IATR
Dr. Sulaiman Al Habib Medical Services Group 4013 215.00 SAR 109.45 SAR −49% vs IATR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Athens Medical C.S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Athens Medical C.S.A. Fair Value". https://www.fairvalue-calculator.com/stock/IATR

Frequently asked questions

Is Athens Medical C.S.A. (IATR) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €2.28 versus a price of €1.39, about +64% upside (undervalued).
What is the fair value of IATR?
Our model-based fair value for Athens Medical C.S.A. is €2.28 (as of Nov 8, 2026), built from audited fundamentals. The current price: €1.39.
What is the quality score of IATR?
Athens Medical C.S.A. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Athens Medical C.S.A. (IATR)?
Our model-based price target is the fair value of €2.28 (as of Nov 8, 2026) from 2 valuation models. Cautious scenario €1.34, optimistic scenario €3.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Athens Medical C.S.A. stock forecast for 2026?
Our models put fair value at €2.28, about +64% upside versus a price of €1.39 (undervalued). Cautious scenario €1.34, optimistic scenario €3.22. The calculation is refreshed regularly with new filings.
What is the revenue of Athens Medical C.S.A. (IATR)?
Athens Medical C.S.A. reported trailing-twelve-month revenue of about €276M (latest available figure, as of Nov 8, 2026).
Does Athens Medical C.S.A. pay a dividend?
Athens Medical C.S.A. currently shows a dividend yield of 1.30% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Athens Medical C.S.A. (IATR)?
Athens Medical C.S.A. has a dividend yield of 1.3%.
What is the intrinsic value of Athens Medical C.S.A. (IATR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Athens Medical C.S.A. it is €2.28 per share (as of Nov 8, 2026), against a price of €1.39. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Athens Medical C.S.A. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, IATR trades below its calculated fair value: price €1.39, fair value €2.28, a gap of about +64% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IATR?
No. The price is what the market pays today (€1.39); the fair value is what the company's own numbers justify (€2.28). For Athens Medical C.S.A. the two are €0.8900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Athens Medical C.S.A. worth?
The market values Athens Medical C.S.A. at about €121M (market capitalisation, as of Nov 8, 2026). Per share that is €1.39; our models calculate a fair value of €2.28 per share.
What do the bullish and bearish scenarios say about IATR?
Our models span a range for Athens Medical C.S.A.: cautious scenario €1.34, base €2.28, optimistic €3.22 per share (as of Nov 8, 2026, price €1.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of IATR?
The PEG ratio of Athens Medical C.S.A. is 0.93 (P/E divided by earnings growth, as of Nov 8, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Athens Medical C.S.A. (IATR)?
Balance-sheet figures for Athens Medical C.S.A. (as of Nov 8, 2026): return on equity −4.3%, debt of 0.58 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is IATR from its 52-week high?
Athens Medical C.S.A. trades at €1.39, about 33% below its 52-week high of €2.06 and 1% above the low of €1.37 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €2.28 is for.
Which stocks are comparable to Athens Medical C.S.A.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Athens Medical C.S.A. stock attractive at the current price?
The data as of Nov 8, 2026: price €1.39, calculated fair value €2.28 (+64%), Quality Score 33/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IATR calculated?
We run Athens Medical C.S.A. through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of €2.28 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Athens Medical C.S.A. currently trades 39% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Athens Medical C.S.A. (IATR)?
The closing price on Nov 9, 2026 was €1.39. Our model-based fair value is €2.28, about +64% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Athens Medical C.S.A. right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. A fairly wide model range (€1.34 to €3.22) leaves room in how you read the outcome.

Key figures of Athens Medical C.S.A.

How large is the market capitalisation of Athens Medical C.S.A. (IATR)?
The market capitalisation of Athens Medical C.S.A. is €121M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Athens Medical C.S.A. (IATR)?
The price-to-sales ratio of Athens Medical C.S.A. is 0.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Athens Medical C.S.A. (IATR)?
Earnings per share at Athens Medical C.S.A. are €−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Athens Medical C.S.A. (IATR)?
The dividend yield of Athens Medical C.S.A. is 1.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Athens Medical C.S.A. (IATR)?
The net margin of Athens Medical C.S.A. is −1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Athens Medical C.S.A. (IATR)?
The return on equity (ROE) of Athens Medical C.S.A. is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Athens Medical C.S.A. (IATR)?
On an EBIT basis the return on assets of Athens Medical C.S.A. is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Athens Medical C.S.A. (IATR)?
The operating margin of Athens Medical C.S.A. is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Athens Medical C.S.A. (IATR)?
Revenue at Athens Medical C.S.A. is growing +3.8% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Athens Medical C.S.A. (IATR)?
Earnings per share at Athens Medical C.S.A. are growing −85.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Athens Medical C.S.A. (IATR) generate?
The free cash flow of Athens Medical C.S.A. is −€11.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Athens Medical C.S.A. (IATR) carry?
The net debt of Athens Medical C.S.A. is €129M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Athens Medical C.S.A. in the live analysis

One click puts Athens Medical C.S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.